Case Studies

Discover how leading research institutions and pharmaceutical companies are using PharmabuddyAI to transform biomarker discovery and precision medicine.

oncologyNovaCure Therapeutics

Precision Medicine in Non-Small Cell Lung Cancer

How NovaCure identified novel biomarkers for immunotherapy response in NSCLC patients, improving response rates by 37%.

neurologyNeuroGenix Research Institute

Early Biomarkers for Alzheimer's Disease

Discovering blood-based biomarkers for early Alzheimer's detection 5-7 years before symptom onset.

immunologyImmunoCore Therapeutics

Stratifying Patients with Autoimmune Disorders

How patient stratification based on biomarker profiles led to a 42% improvement in treatment outcomes for rheumatoid arthritis.

cardiologyCardioHealth Systems

Predictive Biomarkers for Heart Failure

Identifying novel biomarkers that predict heart failure risk with 83% accuracy, enabling preventive interventions.

rare diseasesRareGen Therapeutics

Biomarker Discovery in Rare Genetic Disorders

Accelerating diagnosis and treatment development for rare diseases through AI-powered biomarker identification.

clinical trialsGlobal Pharma Research Consortium

Optimizing Clinical Trial Design with AI

How biomarker-based patient selection reduced trial failure rates by 28% and accelerated time-to-market by 14 months.

Want to become our next success story?

Schedule a demo to see how PharmabuddyAI can accelerate your biomarker discovery and precision medicine initiatives.